Veru Q3 net loss narrows on lower G&A expenses

Veru

10/08/2026 11:41

Overview
US biopharmaceutical firm's fiscal Q3 net loss narrowed yr/yr
Company fully enrolled Phase 2b PLATEAU clinical trial for obesity, exceeding target enrollment
Veru announced clinical supply agreement with Novo Nordisk and received USPTO patent notice

Outlook
Company expects topline data from Phase 2b PLATEAU trial in Q4 2027
Veru plans to prioritize internal cash for enobosarm development, focusing on the PLATEAU trial

Result Drivers
HIGHER R&D EXPENSES: Research and development expenses increased to $4.4 million from $3.0 million
LOWER G&A EXPENSES: General and administrative expenses decreased to $3.4 million from $5.0 million

Company press release: ID:nGNXbKN45x

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
 
$0.30
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Veru Inc. is $24.50, about 951.5% above its August 7 closing price of $2.33

Reuters Recommended Reads
Aug 7 - ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Aug 7 - ANI Pharmaceuticals Q2 adjusted EPS beats on increased volume in specialty areas
Aug 7 - Rapid Micro Biosystems Q2 revenue beats; reaffirms 2026 revenue forecast

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)